The Value of Targeting CXCR4 With 68Ga-Pentixafor PET/CT for Subtyping Primary Aldosteronism
Authors' conclusion
68Ga-Pentixafor PET/CT is a reliable and noninvasive functional imaging technique that demonstrates high accuracy in classifying PA and provides valuable guidance for clinical treatment decision-making.
Study context
- Population
- Patients with primary aldosteronism (PA) or nonfunctional adenoma (NFA); 66 aldosterone-producing adenoma (APA), 33 idiopathic hyperaldosteronism (IHA), 21 NFA
- Participants
- 120 patients
- Outcome
- Detection of APA (visual analysis)
Methodological detailsprospective
- Prospective
Performance
As reported in the abstract
| Test or model | Sensitivity | Specificity | Accuracy |
|---|---|---|---|
| 68Ga-Pentixafor PET/CT | 92.40% | 94.40% | 93.33% |
68Ga-Pentixafor PET/CT
Sensitivity92.40%
Specificity94.40%
Accuracy93.33%
Further findings
| Outcome | Values |
|---|---|
| APA with nodule >1 cm, SUVmax ≥7.3 | 68Ga-Pentixafor PET/CT specificity 100% |
APA with nodule >1 cm, SUVmax ≥7.3
- High sensitivity for APA with nodule <1 cm
Concordance with adrenal venous sampling (AVS) for PA subtyping
- Concordance rate (AVS successful in 5 patients)
- 60%
Adrenalectomy (n=77)
- PET/CT scans with positive lesions, all benefited from surgery
- 61
Concordance with CYP11B2
- Concordance rate
- 81.69%
Original publication
The Value of Targeting CXCR4 With 68Ga-Pentixafor PET/CT for Subtyping Primary Aldosteronism. J Clin Endocrinol Metab. Published 21 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →